权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nicotinic Receptors and Schizophrenia

烟碱受体和精神分裂症

基本信息

批准号：
8819188
负责人：
Robert Freedman
金额：
--
依托单位：
VA EASTERN COLORADO HEALTH CARE SYSTEM
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-10-01 至 2016-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8819188
关键词：
Acetylcholine Adverse effects Antipsychotic Agents Basic Science Body Weight decreased Cholinergic Receptors Clinical Clinical Research Clinical Trials Clinical effectiveness Clozapine Cognition Cognitive Consensus Data Development Dopamine Receptor Double-Blind Method Double-blind trial Effectiveness Generations Goals Metabolic Metabolic syndrome Morbidity - disease rate National Institute of Mental Health Neurocognition Neurocognitive Nicotinic Agonists Nicotinic Receptors Outcome Measure Patients Performance Pharmaceutical Preparations Phase Phase II Clinical Trials Placebos Presynaptic Terminals Property Psychometrics Randomized Resistance Risperidone Safety Schizophrenia Serotonin Receptors 5-HT-3 Symptoms Testing Therapeutic Therapeutic Effect Toxic effect Veterans acetylcholine receptor agonist anabaseine base cholinergic clinical effect cooperative study drug development experience functional outcomes improved mortality neurotransmission novel therapeutics olanzapine phase 2 study presynaptic primary outcome programs public health relevance receptor secondary outcome

项目摘要

DESCRIPTION (provided by applicant): Although a number of antipsychotic drugs are available for Veterans with schizophrenia, three are used more frequently by VA prescribers-risperidone because of its overall favorable side effect profile, clozapine because of its superior efficacy, and olanzapine for many Veterans who do not respond completely to risperidone, but who also cannot take clozapine for various reasons. However, olanzapine, despite its persistent clinical use for patients resistant to safer drugs, produces significant morbidity and mortality from metabolic syndrome. Basic science and clinical studies suggest that one mechanism of the enhanced efficacy of clozapine and olanzapine is increased cholinergic neurotransmission, produced by the increased release of acetylcholine from presynaptic terminals. This effect possibly results from clozapine's and olanzapine's antagonism of serotonergic receptors like the 5-HT3 receptors on cholinergic terminals, which normally decrease acetylcholine release. We have preliminary data showing that the combination of risperidone, to achieve dopamine receptor blockade, and the investigational nicotinic agonist 3-(2,4-dimethoxy)benzylidene anabaseine (DMXB-A) has effects on neurocognition in schizophrenia of similar magnitude to olanzapine. DMXB-A does not significantly enhance the neurocognitive effect of olanzapine, consistent with the hypothesis that olanzapine is already activating cholinergic receptors. We therefore propose a randomized double-blind Phase 2 clinical trial in 60 veterans to test whether patients who currently are judged by their VA clinicians to require olanzapine can be safely and effectively treated with a risperidone DMXB-A combination. The primary outcome measure will be the NIMH MATRICS Consensus Cognitive Battery Total Scale Score, chosen because of its correlation with functional outcomes and its favorable psychometric properties. We hypothesize superiority of risperidone/DMXBA to risperidone/placebo and non-inferiority between risperidone/DMXB-A and olanzapine for neurocognition and clinical ratings, but improvement in metabolic parameters on the risperidone/DMXB-A combination. This phase 2 study will enable us to determine if a longer, more definitive trial, perhaps through the VA Cooperative Studies Program, is warranted.

描述（由申请人提供）：